Literature DB >> 16237223

Assay validation for identification of hereditary nonpolyposis colon cancer-causing mutations in mismatch repair genes MLH1, MSH2, and MSH6.

Madhuri Hegde1, Maria Blazo, Belinda Chong, Tom Prior, Carolyn Richards.   

Abstract

Hereditary nonpolyposis colon cancer (HNPCC, Online Mendelian Inheritance in Man (OMIM) 114500) is an autosomal dominant disorder that is genetically heterogeneous because of underlying mutations in mismatch repair genes, primarily MLH1, MSH2, and MSH6. One challenge to correctly diagnosing HNPCC is that the large size of the causative genes makes identification of mutations both labor intensive and expensive. We evaluated the usefulness of denaturing high performance liquid chromatography (DHPLC) for scanning mismatch repair genes (MLH1, MSH2, and MSH6) for point mutations, small deletions, and insertions. Our assay consisted of 51 sets of primers designed to amplify all exons of these genes. All polymerase chain reaction reactions were amplified simultaneously using the same reaction conditions in a 96-well format. The amplified products were analyzed by DHPLC across a range of optimum temperatures for partial fragment denaturation based on the melting profile of each specific fragment. DNA specimens from 23 previously studied HNPCC patients were analyzed by DHPLC, and all mutations were correctly identified and confirmed by sequence analysis. Here, we present our validation studies of the DHPLC platform for HNPCC mutation analysis and compare its merits with other scanning technologies. This approach provides greater sensitivity and more directed molecular analysis for clinical testing in HNPCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237223      PMCID: PMC1888496          DOI: 10.1016/S1525-1578(10)60584-3

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  53 in total

1.  Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis.

Authors:  A C Jones; J Austin; N Hansen; B Hoogendoorn; P J Oefner; J P Cheadle; M C O'Donovan
Journal:  Clin Chem       Date:  1999-08       Impact factor: 8.327

2.  Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection.

Authors:  M C O'Donovan; P J Oefner; S C Roberts; J Austin; B Hoogendoorn; C Guy; G Speight; M Upadhyaya; S S Sommer; P McGuffin
Journal:  Genomics       Date:  1998-08-15       Impact factor: 5.736

3.  A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers.

Authors:  N Arnold; E Gross; U Schwarz-Boeger; J Pfisterer; W Jonat; M Kiechle
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

4.  Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer.

Authors:  C E Bronner; S M Baker; P T Morrison; G Warren; L G Smith; M K Lescoe; M Kane; C Earabino; J Lipford; A Lindblom
Journal:  Nature       Date:  1994-03-17       Impact factor: 49.962

Review 5.  Molecular diagnostics of cancer predisposition: hereditary non-polyposis colorectal carcinoma and mismatch repair defects.

Authors:  T Bocker; J Rüschoff; R Fishel
Journal:  Biochim Biophys Acta       Date:  1999-05-31

6.  Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis.

Authors:  M P de Leon; M Pedroni; P Benatti; A Percesepe; C Di Gregorio; M Foroni; G Rossi; M Genuardi; G Neri; F Leonardi; A Viel; E Capozzi; M Boiocchi; L Roncucci
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

Review 7.  Public health perspectives on testing for colorectal cancer susceptibility genes.

Authors:  S S Coughlin; D S Miller
Journal:  Am J Prev Med       Date:  1999-02       Impact factor: 5.043

8.  hMLH1, hMSH2 and hMSH6 mutations in hereditary non-polyposis colorectal cancer families from southern Sweden.

Authors:  M Planck; A Koul; E Fernebro; A Borg; U Kristoffersson; H Olsson; E Wenngren; P Mangell; M Nilbert
Journal:  Int J Cancer       Date:  1999-10-08       Impact factor: 7.396

9.  A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC.

Authors:  E Gross; N Arnold; J Goette; U Schwarz-Boeger; M Kiechle
Journal:  Hum Genet       Date:  1999 Jul-Aug       Impact factor: 4.132

View more
  9 in total

1.  De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one.

Authors:  Ajay Goel; Thuy-Phuong Nguyen; Hon-Chiu E Leung; Takeshi Nagasaka; Jennifer Rhees; Erin Hotchkiss; Mildred Arnold; Pia Banerji; Minoru Koi; Chau-To Kwok; Deborah Packham; Lara Lipton; C Richard Boland; Robyn L Ward; Megan P Hitchins
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

2.  The germline MLH1 K618A variant and susceptibility to Lynch syndrome-associated tumors.

Authors:  Fabiola Medeiros; Noralane M Lindor; Fergus J Couch; W Edward Highsmith
Journal:  J Mol Diagn       Date:  2012-03-13       Impact factor: 5.568

3.  Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome.

Authors:  L Raskin; F Schwenter; M Freytsis; M Tischkowitz; N Wong; G Chong; S A Narod; D A Levine; F Bogomolniy; M Aronson; S N Thibodeau; K S Hunt; G Rennert; S Gallinger; S B Gruber; W D Foulkes
Journal:  Clin Genet       Date:  2010-12-14       Impact factor: 4.438

4.  Mutational analysis of thyroid transcription factor-1 gene (TTF-1) in lung carcinomas.

Authors:  Xiao Yan Bai; Hong Shen
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-12-11       Impact factor: 2.416

5.  An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC.

Authors:  Yael Goldberg; Rinnat M Porat; Inbal Kedar; Chen Shochat; Daliah Galinsky; Tamar Hamburger; Ayala Hubert; Hana Strul; Revital Kariiv; Liat Ben-Avi; Moran Savion; Eli Pikarsky; Dvorah Abeliovich; Dani Bercovich; Israela Lerer; Tamar Peretz
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

6.  Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.

Authors:  Gasper Berginc; Matej Bracko; Metka Ravnik-Glavac; Damjan Glavac
Journal:  Fam Cancer       Date:  2009-06-13       Impact factor: 2.375

7.  Microsatellite instability in pediatric high grade glioma is associated with genomic profile and differential target gene inactivation.

Authors:  Marta Viana-Pereira; Alicia Lee; Sergey Popov; Dorine A Bax; Safa Al-Sarraj; Leslie R Bridges; João N Stávale; Darren Hargrave; Chris Jones; Rui M Reis
Journal:  PLoS One       Date:  2011-05-26       Impact factor: 3.240

8.  Suspected Lynch syndrome associated MSH6 variants: A functional assay to determine their pathogenicity.

Authors:  Hellen Houlleberghs; Anne Goverde; Jarnick Lusseveld; Marleen Dekker; Marco J Bruno; Fred H Menko; Arjen R Mensenkamp; Manon C W Spaander; Anja Wagner; Robert M W Hofstra; Hein Te Riele
Journal:  PLoS Genet       Date:  2017-05-22       Impact factor: 5.917

9.  Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch Syndrome.

Authors:  Nayê Balzan Schneider; Tatiane Pastor; André Escremim de Paula; Maria Isabel Achatz; Ândrea Ribeiro Dos Santos; Fernanda Sales Luiz Vianna; Clévia Rosset; Manuela Pinheiro; Patricia Ashton-Prolla; Miguel Ângelo Martins Moreira; Edenir Inêz Palmero
Journal:  Cancer Med       Date:  2018-03-25       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.